Boston Cell Standards’ immunohistochemistry reference materials have entered the FDA’s Medical Device Development Tools qualification phase, advancing efforts to standardize IHC assay performance in cancer diagnostics.
Foundation Medicine will acquire SAGA Diagnostics’ Pathlight MRD platform, expanding its cancer monitoring portfolio. The $595 million deal is expected to close by Q3 2026, with integration supporting treatment selection and recurrence monitoring.
The partnership with Zipline aims to reduce turnaround times for results by transporting samples between hospitals and laboratories.
The regional laboratory will use the Concentriq platform to expand diagnostic services and streamline clinical workflows across its network.
Seegene unveiled its STAgora real-time data analytics platform and an updated CURECA automated PCR system at ESCMID Global 2026, aiming to enhance infectious disease monitoring through integrated laboratory workflows and aggregated test data.
The agreement aims to increase the availability of therapeutic drug monitoring tests for psychiatry and oncology patients using existing laboratory equipment.
The ViaPlex 2-Color Cell Barcoding Kit uses two reactive fluorescent dyes to combine up to 15 distinct cell populations in one tube, reducing reagent use and run time.
The test allows for simultaneous detection of multiple viruses on a sample-to-answer platform designed for immunocompromised patients.
The study will analyze three key proteins to determine if blood-based biomarkers can provide an earlier and more accessible diagnostic method.
The collaboration focuses on creating sensitive assays for a common genetic risk factor to guide drug development and clinical trials.
A proof-of-concept study shows that bacteria-metabolized molecules enriched with carbon-13 produce detectable exhaled CO2, enabling rapid infection identification with inexpensive infrared scanners.
Optical genome mapping detected clinically significant genetic variants missed by standard tests in nearly 20% of acute leukemia cases, according to a 200-patient study.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
A rapid urine test identified effective UTI antibiotics in an average of 5.85 hours, matching standard lab accuracy in a University of Reading study published in the Journal of Antimicrobial Chemotherapy.